Baird raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $41 and keeps an Outperform rating on the shares. The firm updated its model following solid Q4 results and an outlook above consensus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences reports Q4 EPS (8c), consensus (26c)
- Castle Biosciences sees 2026 revenue $340M-$350M, consensus $333.84M
- Castle Biosciences Posts Modest 2025 Growth Amid Headwinds
- Castle Biosciences price target raised to $50 from $36 at KeyBanc
- Castle Biosciences price target raised to $47 from $43 at Guggenheim